Results 311 to 320 of about 356,633 (356)
Some of the next articles are maybe not open access.
Ivosidenib in acute myeloid leukemia
Expert Opinion on Pharmacotherapy, 2023Traditional treatment strategies for acute myeloid leukemia (AML) have primarily relied on standard chemotherapy regimens for four decades. Indeed, the landscape of AML therapy has evolved substantially in recent years, mainly due to the introduction of hypomethylating agents and small molecules.Bcl2 inhibitor venetoclax, Fms-like tyrosine kinase 3 ...
Bruzzese, Antonella +10 more
openaire +2 more sources
Immunotherapy of Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology, 2001Most patients with acute myeloid leukemia (AML) respond initially to combination chemotherapy but later relapse. These patients often die from progressive disease or toxicities of further chemotherapy. At relapse, the patients' blasts are usually resistant to the drugs to which the patient has been exposed and frequently to other cytotoxic agents as ...
A E, Frankel +3 more
openaire +2 more sources
Transplantation in Acute Myeloid Leukemia
Hematology/Oncology Clinics of North America, 2014Acute myeloid leukemia (AML) is associated with poor outcome mainly because of relapse. The best antileukemic treatment is allogeneic stem cell transplantation. However, the associated significant nonrelapse mortality limits both the application and outcome of the procedure.
Tsila, Zuckerman, Jacob M, Rowe
openaire +2 more sources
Acute myeloid leukemia in adults
Current Treatment Options in Oncology, 2000The treatment outcome for most adults with acute myeloid leukemia (AML) remains unacceptable. Additional agents or substitution of high-dose cytarabine for conventional-dose cytarabine during induction does not improve the remission rate or overall survival. There is substantial toxicity with high-dose cytarabine during induction.
L D, Cripe, S, Hinton
openaire +2 more sources
SEPHguarding acute myeloid leukemia
Cell Stem Cell, 2022Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this issue of Cell Stem Cell, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as an opportunity for targeted mitigation of malignant cell growth in AML.
Malini, Gupta, Britta, Will
openaire +2 more sources
Tipifarnib in acute myeloid leukemia
Drugs of Today, 2007Treatment of older patients with acute myeloid leukemia (AML) represents a significant challenge. There is little evidence that outcomes are improving for patients subjected to conventional intensive treatment. In addition, there is a large population of patients who are not considered fit for a more intensive treatment approach, and treatment options ...
Alan K, Burnett, Jonathan, Kell
openaire +2 more sources
Decitabine in Acute Myeloid Leukemia
Seminars in Hematology, 2005Standard induction chemotherapy, depending on patient tolerability, is at present the treatment of choice in patients with acute myeloid leukaemia (AML) under the age of 75 years. Since AML is a disease primarily of the elderly, a large proportion of patients do not receive this therapy; therefore, novel treatment modalities are warranted. In addition,
Lübbert, Michael, Minden, Mark
openaire +3 more sources
Pharmacogenomics in Acute Myeloid Leukemia
Pharmacogenomics, 2009Acute myeloid leukemia (AML) in adults is a heterogeneous malignant pathology with a globally unfavorable prognosis. The classification of AML allows identification of subgroups with favorable prognosis. However, besides these specific subgroups, most patients will have an intermediate or unfavorable prognosis often resulting in induction failure ...
Christophe, Roumier, Meyling H, Cheok
openaire +2 more sources
Immunotherapy for acute myeloid leukemia
Current Oncology Reports, 2005Immunotherapeutic strategies have become part of standard cancer treatment. Chimeric and humanized antibodies have demonstrated activity against a variety of tumors. Although the humanized anti-CD33 antibody HuM195 has only modest activity against overt acute myeloid leukemia (AML), it can eliminate minimal residual disease in acute promyelocytic ...
openaire +2 more sources
Treatment of Acute Myeloid Leukemia
2010The acute myeloid leukemias (AML) represent a heterogeneous group of malignancies derived from the pluripotent hematopoietic stem cell. These leukemias are generally characterized by genetic lesions that result in a combination of defects causing unregulated proliferation of cells and defects in cellular maturation (Gilliland and Griffin 2002).
Gibson, B +3 more
openaire +3 more sources